199 related articles for article (PubMed ID: 18818971)
1. Expression and secretion of endostatin in thyroid cancer.
Hoffmann S; Wunderlich A; Lingelbach S; Musholt PB; Musholt TJ; von Wasielewski R; Zielke A
Ann Surg Oncol; 2008 Dec; 15(12):3601-8. PubMed ID: 18818971
[TBL] [Abstract][Full Text] [Related]
2. [Growth and invasion in differentiated thyroid carcinoma. Function of different growth factors].
Hölting T; Duh OY; Clark OH; Herfarth C
Chirurg; 1994 Dec; 65(12):1100-6. PubMed ID: 7851142
[TBL] [Abstract][Full Text] [Related]
3. Differential pattern of integrin receptor expression in differentiated and anaplastic thyroid cancer cell lines.
Hoffmann S; Maschuw K; Hassan I; Reckzeh B; Wunderlich A; Lingelbach S; Zielke A
Thyroid; 2005 Sep; 15(9):1011-20. PubMed ID: 16187909
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor binding protein production in human follicular thyroid carcinoma cells.
Bachrach LK; Nänto-Salonen K; Tapanainen P; Rosenfeld RG; Gargosky SE
Growth Regul; 1995 Jun; 5(2):109-18. PubMed ID: 7542953
[TBL] [Abstract][Full Text] [Related]
5. Targeting the proteasome as a promising therapeutic strategy in thyroid cancer.
Wunderlich A; Arndt T; Fischer M; Roth S; Ramaswamy A; Greene BH; Brendel C; Hinterseher U; Bartsch DK; Hoffmann S
J Surg Oncol; 2012 Mar; 105(4):357-64. PubMed ID: 22006286
[TBL] [Abstract][Full Text] [Related]
6. Pleiotropic effects of thyroid stimulating hormone in a differentiated thyroid cancer cell line. Studies on proliferation, thyroglobulin secretion, adhesion, migration and invasion.
Zielke A; Hoffmann S; Plaul U; Duh QY; Clark OH; Rothmund M
Exp Clin Endocrinol Diabetes; 1999; 107(6):361-9. PubMed ID: 10543413
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid.
Soh EY; Duh QY; Sobhi SA; Young DM; Epstein HD; Wong MG; Garcia YK; Min YD; Grossman RF; Siperstein AE; Clark OH
J Clin Endocrinol Metab; 1997 Nov; 82(11):3741-7. PubMed ID: 9360534
[TBL] [Abstract][Full Text] [Related]
8. Biphasic effects of thyrotropin on invasion and growth of papillary and follicular thyroid cancer in vitro.
Hoelting T; Tezelman S; Siperstein AE; Duh QY; Clark OH
Thyroid; 1995 Feb; 5(1):35-40. PubMed ID: 7787431
[TBL] [Abstract][Full Text] [Related]
9. Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors--a novel antiproliferative/antiangiogenic strategy in thyroid cancer.
Hoffmann S; Gläser S; Wunderlich A; Lingelbach S; Dietrich C; Burchert A; Müller H; Rothmund M; Zielke A
Langenbecks Arch Surg; 2006 Nov; 391(6):589-96. PubMed ID: 17053904
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of transcription elogation factor A (SII) like 4 (TCEAL4) in anaplastic thyroid cancer.
Akaishi J; Onda M; Okamoto J; Miyamoto S; Nagahama M; Ito K; Yoshida A; Shimizu K
BMC Cancer; 2006 Nov; 6():260. PubMed ID: 17076909
[TBL] [Abstract][Full Text] [Related]
11. Follicular thyroid cancer cells: a model of metastatic tumor in vitro (review).
Hoelting T; Goretzki PE; Duh QY
Oncol Rep; 2001; 8(1):3-8. PubMed ID: 11115561
[TBL] [Abstract][Full Text] [Related]
12. Expression of angiogenesis inhibitors in human bladder cancer may explain rapid metastatic progression after radical cystectomy.
Beecken WD; Engl T; Jonas D; Blaheta RA
Int J Mol Med; 2009 Feb; 23(2):261-6. PubMed ID: 19148551
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of peripheral thyrotropin receptor mRNA in follow-up of differentiated thyroid cancer.
Milas M; Barbosa GF; Mitchell J; Berber E; Siperstein A; Gupta M
Ann Surg Oncol; 2009 Feb; 16(2):473-80. PubMed ID: 19015922
[TBL] [Abstract][Full Text] [Related]
14. Thyrotropin (TSH)-induced production of vascular endothelial growth factor in thyroid cancer cells in vitro: evaluation of TSH signal transduction and of angiogenesis-stimulating growth factors.
Hoffmann S; Hofbauer LC; Scharrenbach V; Wunderlich A; Hassan I; Lingelbach S; Zielke A
J Clin Endocrinol Metab; 2004 Dec; 89(12):6139-45. PubMed ID: 15579770
[TBL] [Abstract][Full Text] [Related]
15. Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation.
Kawachi K; Matsushita Y; Yonezawa S; Nakano S; Shirao K; Natsugoe S; Sueyoshi K; Aikou T; Sato E
Hum Pathol; 2000 Apr; 31(4):428-33. PubMed ID: 10821488
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines.
Hoffmann S; Burchert A; Wunderlich A; Wang Y; Lingelbach S; Hofbauer LC; Rothmund M; Zielke A
Endocrine; 2007 Apr; 31(2):105-13. PubMed ID: 17873319
[TBL] [Abstract][Full Text] [Related]
17. In vitro antiangiogenic activity in ex vivo expanded human limbocorneal epithelial cells cultivated on human amniotic membrane.
Ma DH; Yao JY; Yeh LK; Liang ST; See LC; Chen HT; Lin KY; Liang CC; Lin KK; Chen JK
Invest Ophthalmol Vis Sci; 2004 Aug; 45(8):2586-95. PubMed ID: 15277481
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of valosin-containing protein (p97) is correlated with disease recurrence in follicular thyroid cancer.
Yamamoto S; Tomita Y; Uruno T; Hoshida Y; Qiu Y; Iizuka N; Nakamichi I; Miyauchi A; Aozasa K
Ann Surg Oncol; 2005 Nov; 12(11):925-34. PubMed ID: 16189643
[TBL] [Abstract][Full Text] [Related]
19. Transforming growth factor-beta 1 is a negative regulator for differentiated thyroid cancer: studies of growth, migration, invasion, and adhesion of cultured follicular and papillary thyroid cancer cell lines.
Hölting T; Zielke A; Siperstein AE; Clark OH; Duh QY
J Clin Endocrinol Metab; 1994 Sep; 79(3):806-13. PubMed ID: 8077365
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor enhances proliferation, migration, and invasion of follicular and papillary thyroid cancer in vitro and in vivo.
Hoelting T; Siperstein AE; Clark OH; Duh QY
J Clin Endocrinol Metab; 1994 Aug; 79(2):401-8. PubMed ID: 8045955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
